Single arm clinical study· 2021
Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis
Yu R; Lin Q; Zhai Y; Mao Y; Li K; Gao Y
Microbial biotechnology
- PubMed
- 34318587
- Evidence level
- low
- Verification
- verified
Summary
Open-label clinical study in seborrheic dermatitis: 4 weeks of topical rhTβ4 gel improved scalp flaking, erythema, transepidermal water loss and shifted the scalp microbiome toward a healthy composition more effectively than ketoconazole.
Limitations
Open-label design; no placebo arm; 4-week duration only; single-center Chinese cohort; blinding of assessors not specified; no long-term safety follow-up.